Abstract
Antiarrhythmic drug (AAD) therapy and oral anticoagulation are mainstays of atrial fibrillation (AF) treatment. We studied the use and outcomes of AADs in patients anticoagulated for stroke prophylaxis. Patients randomized in the ROCKET AF trial (n=14,264) were grouped by AAD use at baseline:
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
